A mega-cap healthcare company with a 50+ year history of raising its dividend is a rare find in any market environment, but it becomes especially compelling when that track record is backed by a portfolio of high-demand specialty medicines, next-generation medical devices, and one of the strongest research pipelines in its industry. This company operates across two innovation-driven segments — advanced therapies targeting cancers, immune disorders, and cardiovascular conditions, and a medical technology franchise covering heart recovery systems, robotic surgery, and vision care — giving it a breadth of revenue sources that few healthcare businesses can match. Its beta of 0.26 signals that its share price moves at roughly one-quarter the sensitivity of the broader equity market, making it a standout choice for income-focused investors who want to stay invested without absorbing outsized swings. The company posted worldwide sales approaching $25 billion in its most recently reported quarter, growing at 6.4% on an operational basis despite absorbing several hundred basis points of headwind from biosimilar erosion of a major legacy drug.
The business today is not the sprawling conglomerate it once was. Following the separation of its consumer health division into a standalone public company, this healthcare powerhouse is now focused entirely on high-value, innovation-driven markets where intellectual property, clinical superiority, and regulatory expertise create durable competitive advantages. Ten of its medicine brands posted double-digit revenue growth in the most recent quarter, and its leading cancer therapy surpassed $4 billion in quarterly sales, reinforcing the depth of its commercial portfolio. Its medical technology arm continues to gain share in cardiovascular intervention and is building early momentum in the emerging field of robotic-assisted surgery. The financial profile is just as impressive as the operational one, with more than $20 billion in cash on hand, a net leverage ratio of 0.8x, and a payout ratio of 45% that leaves meaningful room above the dividend to absorb any near-term business volatility without threatening the payment.
This stock has been newly added to the Dividend Protection Stocks Portfolio, a decision grounded in the portfolio’s mandate to hold companies that pair dependable dividend income with meaningful downside protection. Its exceptional dividend safety score, top-ranked low returns risk profile, and 100+ year operating history collectively make it one of the most defensively positioned income investments available in the healthcare sector today.
